Company Overview and News

 
Assa Abloy's (ASAZF) CEO Nico Delvaux on Q3 2018 Results - Earnings Call Transcript

2018-10-19 seekingalpha
Good morning, and welcome to the presentation of Assa Abloy’s results for the Third Quarter 2018. I’m Holger Lembrér, Investor Relations Officer at Assa Abloy. And with me, I have our CEO, Nico Delvaux; and our CFO, Carolina Dybeck Happe. We will kick off with webcast, with the presentation, and then we will open up for questions and answers.
DB GTGP AVCO 0143 MS G11 GTLL

 
David Leyonhjelm to make a run for State Parliament

2018-10-16 smh.com.au
Animal Justice MP Mark Pearson, the almost-vegan caught last year scoffing down oysters and sashimi (“I strayed for that moment”), was elected to the NSW Upper House in 2015 with just 76,000 votes.
GJV NWS NWSA G11 0143

1
GoPro: Revisiting A Tired Story

2018-09-28 seekingalpha
GoPro still trades in the dumps having failed to gain momentum since the 2015 sales peak.
GPRO G11 0143

 
'Squandering his reputation': Michael Clarke savaged for endorsing Australian crypto company

2018-08-09 theage.com.au
If your investment memory doesn’t stretch back to the 1990s when people were going to make an absolute motza raising flightless African birds for meat and feathers, paying up to $40,000 an egg, then it’s worth noting nearly half of ICOs sold in 2017 had already fallen over before March this year.
G11 0143

 
'Squandering his reputation': Michael Clarke savaged for endorsing Australian crypto company

2018-08-09 smh.com.au
If your investment memory doesn’t stretch back to the 1990s when people were going to make an absolute motza raising flightless African birds for meat and feathers, paying up to $40,000 an egg, then it’s worth noting nearly half of ICOs sold in 2017 had already fallen over before March this year.
G11 0143

4
ASSA ABLOY's (ASAZY) CEO Nico Delvaux on Q1 2018 Results - Earnings Call Transcript

2018-04-29 seekingalpha
Okay. Good morning. Good morning, everybody here in the room. Good morning and perhaps good afternoon to some of you on the conference call. My name is Nico Delvaux. I'm the new CEO of ASSA ABLOY. And we'll present to you quarter 1 results. But before I start with the results, as most of you perhaps don't know me that well, couple of words about myself. I'm a Belgian citizen. I'm 51 years old. I've an electromechanical engineer and also have an MBA.
DB G11 0143

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...